BioSpace News Archive

Drug Development

XW Labs Initiates First-in-Human Phase I Study for Novel Narcolepsy Treatment

XW Laboratories Inc. announced the initiation of a Phase 1 single ascending dose (SAD) study in healthy subjects in Australia for its novel proprietary compound XW10172 to assess safety, tolerability and pharmacokinetics.

March 12, 2018
·
1 min read
Business

Immunovia Announces Financial Targets

The Board of Directors of Immunovia AB has adopted financial targets due to the fact the Company, as previously announced, will begin sales during second half of 2018.

March 12, 2018
·
2 min read
Drug Development

Realm Therapeutics Provides Clinical Update, including Results from a Phase 2 Study of PR013 in Allergic Conjunctivitis

Phase 2 study of PR013, a topical ophthalmic solution for the treatment of Allergic Conjunctivitis, did not demonstrate efficacy.

March 12, 2018
·
3 min read
Drug Development

Alnylam Retains Global Rights to Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)

Company plans to accelerate development with Phase 3 start in late 2018.

March 12, 2018
·
9 min read
BioMidwest

Cost of Sleepiness Too Pricey to Ignore

Sleep deprivation impacts workplace safety, productivity and individual health.

March 12, 2018
·
6 min read
Business

Syros Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones

Announced global collaboration with Incyte to use proprietary gene control platform to identify novel therapeutic targets in myeloproliferative neoplasms.

March 12, 2018
·
14 min read
Drug Development

Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

ARO-AAT is the first clinical candidate to utilize Arrowhead’s proprietary Targeted RNAi Molecule (TRiMTM) technology.

March 12, 2018
·
3 min read
Job Trends

XableCath Granted United States Patent for its Peripheral Arterial Catheters

Company receives second patent related to tissue contact control.

March 12, 2018
·
2 min read
Deals

Biogen to Acquire from Pfizer First-in-Class Phase 2b Ready Asset for Cognitive Impairment Associated with Schizophrenia

PF-04958242 is an AMPA receptor potentiator designed to facilitate neurotransmission.

March 12, 2018
·
5 min read
Business

Lipocine Announces Financial and Operational Results for the Fiscal Year Ended December 31, 2017

Specialty pharmaceutical company today announced financial results for the fourth quarter and fiscal year ended December 31, 2017.

March 12, 2018
·
15 min read